Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis

Annals of the Rheumatic Diseases
J BraunJ Sieper

Abstract

To obtain results of the second year extension of an original 3 month randomised, placebo controlled trial (and the 1 year extension study) assessing the use of infliximab, a monoclonal antibody to tumour necrosis factor alpha, for the treatment of patients with ankylosing spondylitis (AS). Of the 54 patients with AS who completed the first year of the study, 52 continued to receive infliximab 5 mg/kg every 6 weeks up to week 102. The primary end point was the proportion of patients achieving at least 50% improvement from baseline in the Bath AS Disease Activity Index (BASDAI) at week 102. Other assessments included patient and physician global assessments, quality of life as assessed by Short Form-36, Bath AS Functional Index, Bath AS Metrology Index, and C reactive protein (CRP). Improvement in signs and symptoms of AS seen during the first year of the study was sustained during the second year. Forty nine patients (71% of 69 enrolled patients and 49/52 (94%) patients who started year 2) completed the study up to week 102. Thirty (58%) patients achieved at least 50% improvement from baseline in the BASDAI score at week 102. Scores for other efficacy assessments were similar at weeks 54 and 102. Median CRP levels remained low ...Continue Reading

References

Feb 14, 2003·The New England Journal of Medicine·Filip BaertPaul Rutgeerts
Apr 13, 2004·Arthritis and Rheumatism·R N MainiUNKNOWN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

❮ Previous
Next ❯

Citations

Jun 15, 2007·Inflammatory Bowel Diseases·Arthur Barrie, Miguel Regueiro
Mar 16, 2007·Rheumatology International·Aliki I VenetsanopoulouAlexandros A Drosos
May 28, 2008·Rheumatology International·C DuftnerM Herold
Jun 30, 2009·Rheumatology International·L Goh, A Samanta
May 27, 2008·Wiener medizinische Wochenschrift·Hans-Eckhard Langer
Jun 6, 2007·Current Treatment Options in Gastroenterology·Benjamin Siemanowski, Miguel Regueiro
Jun 21, 2007·International Journal of Technology Assessment in Health Care·Gisela KobeltJürgen Braun
Jun 16, 2005·Current Opinion in Rheumatology·Jane Zochling, Jürgen Braun
Apr 7, 2007·Current Opinion in Rheumatology·Augustine M ManadanJoel A Block
May 5, 2009·Current Opinion in Rheumatology·Nigil Haroon, Robert D Inman
Aug 30, 2005·Annals of the Rheumatic Diseases·J ZochlingUNKNOWN European League Against Rheumatism
Oct 14, 2006·Annals of the Rheumatic Diseases·D E FurstM H Weisman
Nov 21, 2007·Annals of the Rheumatic Diseases·D E FurstM E Weinblatt
Jan 13, 2012·Journal of Medical Case Reports·Mohd Shahrir Mohamed SaidMohd Shahdan Shahid
Jan 6, 2011·Arthritis Research & Therapy·Andrew Barr, Andrew Keat
Jun 1, 2007·Biologics : Targets & Therapy·Rebecca Grainger, Andrew A Harrison
Apr 13, 2007·American Journal of Clinical Dermatology·Ziad Reguiaï, Florent Grange
Jan 1, 2014·Rheumatology International·Fatma Ilknur CinarSalih Pay
May 28, 2005·Current Rheumatology Reports·Walter P Maksymowych
Nov 22, 2007·Expert Opinion on Therapeutic Targets·Christoph Ackermann, Arthur Kavanaugh
Apr 1, 2007·Expert Review of Pharmacoeconomics & Outcomes Research·Dean A RegierCarlo A Marra
Apr 13, 2010·Expert Review of Clinical Immunology·Xenofon Baraliakos, Juergen Braun
May 11, 2005·Expert Opinion on Investigational Drugs·Martin Braddock
Jul 30, 2005·Expert Opinion on Biological Therapy·M Rudwaleit, J Sieper
Apr 26, 2006·Expert Opinion on Pharmacotherapy·Jane Zochling, Jürgen Braun
Jan 27, 2006·Expert Opinion on Biological Therapy·Jan Brandt, Jürgen Braun
Feb 5, 2008·Mayo Clinic Proceedings·Sotirios TsiodrasDimitrios P Kontoyiannis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angelman Syndrome

Angelman syndrome is a neurogenetic imprinting disorder caused by loss of the maternally inherited UBE3A gene and is characterized by generalized epilepsy, limited expressive speech, sleep dysfunction, and movement disorders. Here is the latest research.